[go: up one dir, main page]

MA33931B1 - Composition pharmaceutique pour traiter un syndrome métabolique - Google Patents

Composition pharmaceutique pour traiter un syndrome métabolique

Info

Publication number
MA33931B1
MA33931B1 MA35075A MA35075A MA33931B1 MA 33931 B1 MA33931 B1 MA 33931B1 MA 35075 A MA35075 A MA 35075A MA 35075 A MA35075 A MA 35075A MA 33931 B1 MA33931 B1 MA 33931B1
Authority
MA
Morocco
Prior art keywords
metabolic syndrome
treatment
pharmaceutical formula
receptor
hoarding
Prior art date
Application number
MA35075A
Other languages
Arabic (ar)
English (en)
Inventor
Mark Sommerfeld
Hans-Ludwig Schaefer
Oliver Boscheinen
Paul Habermann
Ercole Rao
Matthias Dreyer
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41718306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33931(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA33931B1 publication Critical patent/MA33931B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition pharmaceutique contenant au moins l'un parmi un composé fgf-21 (facteur de croissance des fibroblastes 21), au moins un agoniste de glp-1r (récepteur du peptide analogue au glucagon 1) et facultativement au moins un médicament antidiabétique et/ou au moins un inhibiteur de dpp-4 (dipeptidyl peptidase-4) pour le traitement d'au moins un syndrome métabolique et/ou de l'athérosclérose, en particulier du diabète, de la dyslipidémie, de l'obésité et/ou de l'adiposité.
MA35075A 2010-01-21 2011-01-21 Composition pharmaceutique pour traiter un syndrome métabolique MA33931B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305070A EP2359843A1 (fr) 2010-01-21 2010-01-21 Composition pharmaceutique pour le traitement d'un syndrome métabolique
PCT/EP2011/050793 WO2011089203A1 (fr) 2010-01-21 2011-01-21 Composition pharmaceutique pour le traitement d'un syndrome métabolique

Publications (1)

Publication Number Publication Date
MA33931B1 true MA33931B1 (fr) 2013-01-02

Family

ID=41718306

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35075A MA33931B1 (fr) 2010-01-21 2011-01-21 Composition pharmaceutique pour traiter un syndrome métabolique

Country Status (34)

Country Link
US (4) US20130203651A1 (fr)
EP (7) EP2460527A1 (fr)
JP (3) JP5925130B2 (fr)
KR (2) KR20120123445A (fr)
CN (1) CN102753192B (fr)
AR (1) AR079939A1 (fr)
AU (2) AU2011208650B2 (fr)
BR (1) BR112012017949A2 (fr)
CA (1) CA2787131A1 (fr)
CL (1) CL2012002031A1 (fr)
CO (1) CO6592082A2 (fr)
CY (2) CY1116026T1 (fr)
DK (2) DK2525807T3 (fr)
ES (3) ES2703581T3 (fr)
HK (1) HK1259492A1 (fr)
HR (2) HRP20150029T1 (fr)
HU (1) HUE041442T2 (fr)
IL (2) IL220862A0 (fr)
LT (1) LT3216459T (fr)
MA (1) MA33931B1 (fr)
MX (2) MX361922B (fr)
NZ (1) NZ601306A (fr)
PH (1) PH12012501403B1 (fr)
PL (2) PL2525807T3 (fr)
PT (2) PT2525807E (fr)
RS (1) RS53742B1 (fr)
RU (2) RU2732703C2 (fr)
SG (2) SG182652A1 (fr)
SI (2) SI2525807T1 (fr)
TR (1) TR201820147T4 (fr)
TW (2) TWI623320B (fr)
UY (1) UY33194A (fr)
WO (1) WO2011089203A1 (fr)
ZA (1) ZA201204996B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2349324T (lt) 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
EP2460527A1 (fr) * 2010-01-21 2012-06-06 Sanofi Composition pharmaceutique pour le traitement d'un syndrome métabolique
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
ES2748038T3 (es) 2011-07-01 2020-03-12 Ngm Biopharmaceuticals Inc Composiciones, usos y métodos para el tratamiento de trastornos y enfermedades metabólicos
EP2548570A1 (fr) * 2011-07-19 2013-01-23 Sanofi Composition pharmaceutique pour le traitement d'un syndrome métabolique
TWI559929B (en) * 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9458214B2 (en) * 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
BR112015004734A2 (pt) * 2012-09-07 2017-11-21 Sanofi Sa proteínas de fusão para tratar uma síndrome metabólica
EP2925775B1 (fr) 2012-11-28 2020-09-16 NGM Biopharmaceuticals, Inc. Compositions et méthodes de traitement de troubles et maladies métaboliques
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
EP2938740B1 (fr) 2012-12-27 2022-04-20 NGM Biopharmaceuticals, Inc. Peptides chimériques fgf19 pour l'utilisation dans le traitement de maladies de l'acide biliaire
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
KR102178945B1 (ko) 2013-10-28 2020-11-13 엔지엠 바이오파마슈티컬스, 아이엔씨. 암 모델 및 관련 방법
PE20170256A1 (es) 2014-01-24 2017-04-22 Ngm Biopharmaceuticals Inc Proteinas de union y sus metodos de uso
EP3104873B1 (fr) * 2014-02-13 2019-09-04 Technische Universität München Fgf-8 pour son utilisation dans le traitement des maladies ou des troubles de l'homéostasie énergétique
US20170065678A1 (en) 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
SI3139948T1 (sl) * 2014-05-07 2020-07-31 Novo Nordisk A/S Zdravljenje diabetesa tipa 1 z uporabo GLP-1 in anti-IL-21
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
WO2015195509A2 (fr) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Procédés et utilisations pour la modulation de l'homéostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire
CN104383523A (zh) * 2014-10-22 2015-03-04 山西医科大学 Cjc-1131降糖药物在治疗阿尔茨海默病的用途
IL251834B2 (en) 2014-10-23 2023-09-01 Ngm Biopharmaceuticals Inc Pharmaceutical compositions containing peptide variants and methods of using them
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
MA41138B1 (fr) 2014-12-12 2023-07-31 Sanofi Aventis Deutschland Formulation à rapport fixe d'insuline glargine/lixisenatide
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
WO2017019957A2 (fr) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Protéines de liaison et leurs procédés d'utilisation
ES2871036T3 (es) 2015-11-09 2021-10-28 Ngm Biopharmaceuticals Inc Método para el tratamiento de trastornos relacionados con ácidos biliares
WO2018039557A1 (fr) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Méthodes de traitement de cancers et de tumeurs à médiation assurée par le facteur de croissance des fibroblastes 19
CA3047862A1 (fr) * 2016-12-22 2018-06-28 Sanofi Combinaisons d'agonistes du compose fgf21/agoniste du glp-1r ayant un rapport d'activite optimise
JP2018110304A (ja) 2016-12-28 2018-07-12 パナソニックＩｐマネジメント株式会社 監視システム、監視方法、及びプログラム
JP7181886B2 (ja) * 2017-03-14 2022-12-01 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 免疫グロブリンのＦｃ部分を含む二重標的融合タンパク質
CN119386162A (zh) 2017-12-22 2025-02-07 诺华股份有限公司 用fgf21变体治疗代谢障碍的方法
CA3089657A1 (fr) * 2018-01-31 2019-08-08 Sanofi Peptides a chaine b de relaxine lipides modifies et leur utilisation therapeutique
CN110128525B (zh) 2018-02-08 2022-08-26 广东东阳光药业有限公司 Fgf21变体、融合蛋白及其应用
JP2021528422A (ja) * 2018-06-21 2021-10-21 サノフイＳａｎｏｆｉ 最適化された活性比を有するｆｇｆ２１化合物／ｇｌｐ−１ｒアゴニストの組合せ
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
KR20210149366A (ko) * 2020-06-02 2021-12-09 주식회사 고바이오랩 Icam-2에 결합하는 물질을 유효성분으로 포함하는 대사질환 예방 또는 치료용 약학 조성물
US12054551B2 (en) 2020-07-02 2024-08-06 Sanofi FGFR1/KLB targeting agonistic antigen-binding proteins and conjugates thereof with GLP-1R agonistic peptides
KR20230034357A (ko) * 2020-07-02 2023-03-09 사노피 Glp-1r 작용제/fgf21 융합 단백질
TWI817307B (zh) * 2021-01-04 2023-10-01 大陸商華領醫藥技術（上海）有限公司 多扎格列艾汀（ｄｏｒｚａｇｌｉａｔｉｎ）和胰高血糖素樣肽-１類似物的藥物組成物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK347086D0 (da) 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
PT86819B (pt) 1987-02-25 1992-05-29 Novo Industri As Processo para a preparacao de novos derivados da insulina e de composicoes farmaceuticas que os contem
EP0792290B1 (fr) 1993-09-17 2001-08-29 Novo Nordisk A/S Insuline acylee
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
JP2002112772A (ja) * 2000-07-10 2002-04-16 Takeda Chem Ind Ltd 新規ポリペプチドおよびそのｄｎａ
US6689385B2 (en) * 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
AU2002322394A1 (en) 2001-07-30 2003-02-17 Eli Lilly And Company Method for treating diabetes and obesity
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
AU2003273300A1 (en) * 2002-09-06 2004-03-29 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
US20070253966A1 (en) 2003-06-12 2007-11-01 Eli Lilly And Company Fusion Proteins
WO2005061712A1 (fr) 2003-12-10 2005-07-07 Eli Lilly And Company Muteines a facteur de croissance fibroblastique 21
WO2005072769A1 (fr) 2004-01-26 2005-08-11 Eli Lilly And Company Utilisation du fgf-21 et d'une thiazolidinedione dans le traitement du diabete de type 2
CA2557782A1 (fr) 2004-03-17 2005-10-06 Eli Lilly And Company Composes fgf-21 lies au glycol
PT1751184E (pt) 2004-05-13 2009-11-10 Lilly Co Eli Proteínas de fusão de fgf-21
SI1789442T1 (sl) 2004-09-02 2010-01-29 Lilly Co Eli Proteinske mutante fibroblastnega rastnega faktorja 21
WO2006028714A1 (fr) 2004-09-02 2006-03-16 Eli Lilly And Company Muteines du facteur de croissance 21 du fibroblaste
EP3061461A1 (fr) 2004-10-29 2016-08-31 ratiopharm GmbH Remodelage et glycopegylation du facteur de croissance des fibroblastes (fgf)
EP1831371A2 (fr) 2004-12-14 2007-09-12 Eli Lilly And Company Muteines du facteur de croissance fibroblastique 21
WO2008019143A2 (fr) * 2006-08-04 2008-02-14 Amylin Pharmaceuticals, Inc Utilisation d'exendines et d'agonistes d'exendines et d'agonistes du récepteur glp-1 pour modifier la dimension de particule et la composition de sous-classe de lipoprotéines
AR064623A1 (es) * 2006-12-21 2009-04-15 Centocor Inc Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
ES2385114T3 (es) 2007-03-30 2012-07-18 Ambrx, Inc. Polipéptidos de FGF-21 modificados y sus usos
JP2010535781A (ja) * 2007-08-03 2010-11-25 イーライ リリー アンド カンパニー 肥満に対する処置
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations
JP5647899B2 (ja) 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
WO2010006214A1 (fr) * 2008-07-09 2010-01-14 Ambrx, Inc. Anticorps de neutralisation de fgf-21 et leurs utilisations
US20120052069A1 (en) * 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
CN102802657A (zh) * 2009-06-11 2012-11-28 诺沃-诺迪斯克有限公司 用于治疗2型糖尿病的glp-1和fgf21组合
EP2460527A1 (fr) * 2010-01-21 2012-06-06 Sanofi Composition pharmaceutique pour le traitement d'un syndrome métabolique
EP2548570A1 (fr) * 2011-07-19 2013-01-23 Sanofi Composition pharmaceutique pour le traitement d'un syndrome métabolique

Also Published As

Publication number Publication date
DK2525807T3 (en) 2015-02-09
CO6592082A2 (es) 2013-01-02
MX361922B (es) 2018-12-19
TW201141511A (en) 2011-12-01
LT3216459T (lt) 2019-01-10
ZA201204996B (en) 2013-02-27
EP3357503A1 (fr) 2018-08-08
HK1259492A1 (en) 2019-11-29
US20150231210A1 (en) 2015-08-20
PT2525807E (pt) 2015-02-04
IL267980A (en) 2019-08-29
PT3216459T (pt) 2019-01-11
AU2011208650B2 (en) 2016-07-14
DK3216459T3 (en) 2019-01-21
ES2703581T3 (es) 2019-03-11
AU2011208650A1 (en) 2012-08-09
BR112012017949A2 (pt) 2017-06-27
JP5925130B2 (ja) 2016-05-25
JP2013518035A (ja) 2013-05-20
RU2593960C2 (ru) 2016-08-10
AU2016244202A1 (en) 2016-11-03
EP3357503B1 (fr) 2019-10-30
RU2012135686A (ru) 2014-02-27
EP3216459B1 (fr) 2018-09-26
HUE041442T2 (hu) 2019-05-28
PL2525807T3 (pl) 2015-04-30
MX2012008092A (es) 2012-07-30
RS53742B1 (sr) 2015-06-30
CY1116026T1 (el) 2017-01-25
EP2359843A1 (fr) 2011-08-24
KR20180049194A (ko) 2018-05-10
IL220862A0 (en) 2012-09-24
MX336751B (es) 2016-01-29
SG10201500465XA (en) 2015-03-30
JP2016128483A (ja) 2016-07-14
SI2525807T1 (sl) 2015-02-27
US20180236033A1 (en) 2018-08-23
TWI561241B (en) 2016-12-11
TR201820147T4 (tr) 2019-01-21
CL2012002031A1 (es) 2012-12-14
EP3607964B1 (fr) 2022-08-31
RU2016124562A3 (fr) 2019-09-20
EP3216459A1 (fr) 2017-09-13
US20160279199A1 (en) 2016-09-29
CN102753192B (zh) 2015-09-23
ES2529612T3 (es) 2015-02-23
TW201703792A (zh) 2017-02-01
EP2460527A1 (fr) 2012-06-06
EP2754449A1 (fr) 2014-07-16
TWI623320B (zh) 2018-05-11
UY33194A (es) 2011-08-31
EP2525807A1 (fr) 2012-11-28
PH12012501403B1 (en) 2018-12-12
PL3216459T3 (pl) 2019-04-30
JP6521880B2 (ja) 2019-05-29
EP2525807B1 (fr) 2014-11-12
CY1121423T1 (el) 2020-05-29
CN102753192A (zh) 2012-10-24
NZ601306A (en) 2013-11-29
IL267980B (en) 2020-03-31
SI3216459T1 (sl) 2019-02-28
JP2018095659A (ja) 2018-06-21
RU2732703C2 (ru) 2020-09-21
EP3607964A1 (fr) 2020-02-12
KR20120123445A (ko) 2012-11-08
PH12012501403A1 (fr) 2012-10-29
HRP20150029T1 (xx) 2015-03-27
HK1173073A1 (en) 2013-05-10
CA2787131A1 (fr) 2011-07-28
SG182652A1 (en) 2012-08-30
US20130203651A1 (en) 2013-08-08
AR079939A1 (es) 2012-02-29
ES2930750T3 (es) 2022-12-21
AU2016244202B2 (en) 2018-03-01
RU2016124562A (ru) 2018-11-30
WO2011089203A1 (fr) 2011-07-28
HRP20182158T1 (hr) 2019-02-22

Similar Documents

Publication Publication Date Title
MA33931B1 (fr) Composition pharmaceutique pour traiter un syndrome métabolique
HK1207097A1 (en) Fusion proteins for treating a metabolic syndrome
UA114710C2 (uk) Похідне оксинтомодуліну та фармацевтична композиція для запобігання або лікування ожиріння, яка його містить
AR092873A1 (es) Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
PE20220938A1 (es) Compuestos agonistas de gipr
TN2014000096A1 (en) Fibroblast growth factor 21 variants
MA32703B1 (fr) Combinaison d'une insuline et d'un agoniste de glp 1
IN2014MN02132A (fr)
MX2014015258A (es) Variantes del factor 21 de crecimiento de fibroblasto.
CL2007003176A1 (es) Compuestos derivados de nicotinamida, inhibidores de 11betahsd1; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, la diabetes tipo 2, obesidad o aterosclerosis.
MY180661A (en) Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
EA200870472A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
CY1109842T1 (el) Αναστολεις της αφυδρογονασης 11-β-υδροξυστεροειδων i
EA200870475A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
CL2013002414A1 (es) Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension.
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
CL2012003053A1 (es) Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad.
BRPI0924307B8 (pt) análogos de oxintomodulina
CL2009000173A1 (es) Compuestos derivados de urea-tetrahidroxiquinoxalina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y la prevencion de la obesidad y la diabetes, resistencia a la insulina, sindrome metabolico, entre otros.
MY159565A (en) Pharmaceutical composition comprising a glp-1 agonist and methionine
EA201170305A1 (ru) Аналоги глюкозозависимого инсулинотропного полипептида (gip), модифицированные по n-концу
IL195030A (en) Dpp iv inhibitor formulations
CL2013003688A1 (es) Peptido coagonista del receptor de glucagon/glp-1; conjugado de dicho peptido; composicion farmacéutica; uso del peptido para tratar una enfermedad seleccionada del grupo de síndrome metabólico, diabetes, obesidad, esteatosis hepática y una enfermedad neurodegenerativa.
DE602007007473D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
NO20080552L (no) GLP-1 farmasoytiske sammensetninger